Paratek Pharmaceuticals (NASDAQ:PRTK) Rating Increased to Hold at BidaskClub
Several other equities analysts also recently issued reports on PRTK. SVB Leerink cut their price objective on shares of Paratek Pharmaceuticals from $15.00 to $14.00 and set an outperform rating on the stock in a report on Tuesday, August 11th. ValuEngine raised shares of Paratek Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, August 11th. HC Wainwright lifted their price objective on shares of Paratek Pharmaceuticals from $18.00 to $19.00 and gave the stock a buy rating in a research note on Tuesday, August 11th. Finally, Zacks Investment Research downgraded Paratek Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $15.71.
Shares of PRTK opened at $5.83 on Friday. The company has a 50 day moving average of $4.63 and a two-hundred day moving average of $4.43. Paratek Pharmaceuticals has a twelve month low of $2.50 and a twelve month high of $6.41. The company has a market cap of $264.61 million, a price-to-earnings ratio of -1.94 and a beta of 1.53.
Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its position in Paratek Pharmaceuticals by 121.2% during the first quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,570 shares in the last quarter. Citigroup Inc. grew its stake in shares of Paratek Pharmaceuticals by 32.2% during the 1st quarter. Citigroup Inc. now owns 14,227 shares of the specialty pharmaceutical company’s stock worth $45,000 after purchasing an additional 3,469 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Paratek Pharmaceuticals during the 1st quarter worth approximately $49,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Paratek Pharmaceuticals during the 2nd quarter valued at approximately $56,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Paratek Pharmaceuticals in the 1st quarter valued at $61,000. Hedge funds and other institutional investors own 46.77% of the company’s stock.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
Recommended Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.